DekaBank Deutsche Girozentrale’s Voyager Therapeutics VYGR Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-50,000	Closed	-$380K	–	1326
2023 Q1	$380K	Buy	+50,000	New	+$398K	﹤0.01%	1069
2021 Q2	–	Sell	-9,500	Closed	-$45K	–	1418
2021 Q1	$45K	Hold	9,500	–	–	﹤0.01%	1307
2020 Q4	$67K	Hold	9,500	–	–	﹤0.01%	1293
2020 Q3	$104K	Buy	+9,500	New	+$112K	﹤0.01%	1126
2019 Q3	–	Sell	-19,800	Closed	-$521K	–	1128
2019 Q2	$521K	Buy	19,800 +7,700	+64%	+$176K	﹤0.01%	914
2019 Q1	$259K	Buy	12,100 +2,200	+22%	+$28.7K	﹤0.01%	1007
2018 Q4	$89K	Sell	9,900 -2,200	-18%	-$28.2K	﹤0.01%	1074
2018 Q3	$259K	Sell	12,100 -300	-2%	-$5.76K	﹤0.01%	1029
2018 Q2	$252K	Hold	12,400	–	–	﹤0.01%	1015
2018 Q1	$227K	Buy	+12,400	New	+$268K	﹤0.01%	976

Other funds holding VYGR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

DekaBank Deutsche Girozentrale's VYGR Position: Q2 2023 in Review

DekaBank Deutsche Girozentrale sold out of Voyager Therapeutics (VYGR) in Q2 2023, closing a stake of 50,000 shares — an estimated $380K sold.

DekaBank Deutsche Girozentrale first reported a position in VYGR in Q1 2018 and held it in 10 quarters. The position peaked at $521K in Q2 2019. 106 funds tracked by Wall St. Rank hold VYGR as of Q2 2023.

DekaBank Deutsche Girozentrale reported no remaining Voyager Therapeutics position as of Q2 2023 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 50,000 Voyager Therapeutics shares in Q2 2023, an estimated $380K.
DekaBank Deutsche Girozentrale first reported a position in Voyager Therapeutics in Q1 2018 and held it in 10 quarters.
DekaBank Deutsche Girozentrale's Voyager Therapeutics position peaked at $521K in Q2 2019.
106 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2023.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2023, filed 25 Jul 2023.